Related Experiment Video
Updated: Jun 11, 2025
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier MSC for Lung Cancer Screening
Published on: October 26, 2017
MicroRΝΑ analysis in patients with myelodysplastic neoplasms. Possible implications in risk stratification
Stavroula Syriopoulou1, Christina-Nefeli Kontandreopoulou1, Panagiotis T Diamantopoulos1
1Hematology Unit, First Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract:
MiRNAs have been identified as participants in leukemogenesis by controlling several cellular functions, such as differentiation, proliferation, and apoptosis. Their role in myelodysplastic neoplasms (MDS) pathogenesis is researched due to implementations in early identification, classification, and therapeutical options. IPSS-R, being the most widely used MDS classification, underestimates early biological events that can alter the disease's prognosis. The purpose of this study is to determine whether miRNA levels are aligned to MDS risk stratification groups and can therefore be used as diagnostic biomarkers. To evaluate miRNAs as possible biomarkers, we measured the levels of miR-181a-2-3p, miR-124-3p, miR-550a-3p, miR-155-5p, miR-151a-3p, and miR-125b-5p by a quantitative real-time PCR in bone marrow samples of 41 MDS patients. In conclusion, in myeloid malignancies, genomic characteristics may provide a wider apprehension of its clinical course and prognosis. MiRNAs constitute a possible diagnostic biomarker and therapeutic target, allowing intermediate-risk patients that express high levels of specific miRNAs to be re-classified and receive more advanced therapeutic agents. In our study, an association between high levels of miRNAs and worsening outcomes is established, supporting the need for further incorporation of molecular data into currently used classification systems.
Insights
MicroRNAs (miRNAs) show potential as diagnostic biomarkers for myelodysplastic neoplasms (MDS). High miRNA levels in MDS patients correlate with poorer outcomes, suggesting their use in refining risk stratification and treatment.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- MicroRNAs (miRNAs) regulate crucial cellular functions like differentiation, proliferation, and apoptosis, playing a role in leukemogenesis.
- Myelodysplastic neoplasms (MDS) pathogenesis research is driven by the need for improved early detection, classification, and therapeutic strategies.
- Current MDS risk stratification, like the International Prognostic Scoring System-Revised (IPSS-R), may not fully capture early biological events impacting prognosis.
Purpose of the Study:
- To investigate the alignment of specific microRNA (miRNA) levels with myelodysplastic neoplasms (MDS) risk stratification groups.
- To evaluate the potential of miRNAs as diagnostic biomarkers for MDS.
- To explore the utility of miRNAs in refining MDS classification and prognosis.
Main Methods:
- Quantitative real-time PCR was employed to measure the expression levels of six specific miRNAs (miR-181a-2-3p, miR-124-3p, miR-550a-3p, miR-155-5p, miR-151a-3p, and miR-125b-5p).
- Bone marrow samples from 41 MDS patients were analyzed.
- MiRNA expression levels were correlated with established MDS risk stratification groups.
Main Results:
- An association was established between high levels of specific miRNAs and adverse outcomes in MDS patients.
- The study identified potential correlations between miRNA expression profiles and MDS risk categories.
- Findings suggest that specific miRNAs could serve as predictive biomarkers for disease progression.
Conclusions:
- Genomic characteristics, including miRNA expression, offer a more comprehensive understanding of myeloid malignancies' clinical course and prognosis.
- MicroRNAs represent promising diagnostic biomarkers and therapeutic targets in MDS.
- Incorporating molecular data, such as miRNA levels, into existing classification systems could enable re-classification of intermediate-risk patients for more targeted therapies.
